VLT-015
/ Valentech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 21, 2024
VLT-015 in Patients With Schizophrenia
(clinicaltrials.gov)
- P1 | N=15 | Completed | Sponsor: CF Pharma, LLC | Recruiting ➔ Completed
Trial completion • CNS Disorders • Psychiatry • Schizophrenia
August 25, 2022
Phase I of VLT-015 in Patients With Schizophrenia
(clinicaltrials.gov)
- P1 | N=15 | Recruiting | Sponsor: Valentech LLC
New P1 trial • CNS Disorders • Psychiatry • Schizophrenia
1 to 2
Of
2
Go to page
1